A L Byrne1, B J Marais2, C D Mitnick3, F L Garden4, L Lecca3, C Contreras5, Y Yauri6, F Garcia5, G B Marks7. 1. The University of Sydney, Sydney, New South Wales, Australia, Socios En Salud Sucursal Perú, Partners In Health, Lima, Peru, Centre for Research Excellence in Tuberculosis, Sydney, New South Wales. 2. The University of Sydney, Sydney, New South Wales, Australia, Centre for Research Excellence in Tuberculosis, Sydney, New South Wales, Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, New South Wales, Australia. 3. Socios En Salud Sucursal Perú, Partners In Health, Lima, Peru, Harvard Medical School, Boston, Massachusetts, USA. 4. The Woolcock Institute of Medical Research, Sydney, New South Wales, South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Ingham Institute of Applied Medical Research, Sydney, New South Wales, Australia. 5. Socios En Salud Sucursal Perú, Partners In Health, Lima, Peru. 6. Ministry of Health, Red de Salud Lima Ciudad, Lima, Perú. 7. The University of Sydney, Sydney, New South Wales, Australia, Centre for Research Excellence in Tuberculosis, Sydney, New South Wales, The Woolcock Institute of Medical Research, Sydney, New South Wales, South Western Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Ingham Institute of Applied Medical Research, Sydney, New South Wales, Australia.
Abstract
INTRODUCTION: The increasing prevalence of non-communicable diseases (NCDs) poses a major challenge to low- and middle-income countries. Patients' engagement with health services for anti-tuberculosis treatment provides an opportunity for screening for NCDs and for linkage to care. METHODS: We explored the feasibility and yield of screening for NCDs in patients treated for tuberculosis (TB) in Lima, Peru, as part of a study focused on chronic respiratory sequelae. A representative sample of community controls was recruited from the same geographical area. Screening entailed taking a medical history and performing ambulatory blood pressure measurement and urinalysis. RESULTS: A total of 177 participants with previous TB (33 with multidrug-resistant TB) and 161 community controls were evaluated. There was an almost four-fold increased prevalence of self-reported diabetes mellitus (DM) in the TB group (adjusted prevalence ratio 3.66, 95%CI 1.68-8.01). Among those without self-reported DM, 3.3% had glycosuria, with a number needed to screen (NNS) of 31. The NNS to find one (new) case of hypertension or proteinuria in the TB group was respectively 24 and 5. CONCLUSION: Patient-centred care that includes pragmatic NCD screening is feasible in TB patients, and the treatment period provides a good opportunity to link patients to ongoing care.
INTRODUCTION: The increasing prevalence of non-communicable diseases (NCDs) poses a major challenge to low- and middle-income countries. Patients' engagement with health services for anti-tuberculosis treatment provides an opportunity for screening for NCDs and for linkage to care. METHODS: We explored the feasibility and yield of screening for NCDs in patients treated for tuberculosis (TB) in Lima, Peru, as part of a study focused on chronic respiratory sequelae. A representative sample of community controls was recruited from the same geographical area. Screening entailed taking a medical history and performing ambulatory blood pressure measurement and urinalysis. RESULTS: A total of 177 participants with previous TB (33 with multidrug-resistant TB) and 161 community controls were evaluated. There was an almost four-fold increased prevalence of self-reported diabetes mellitus (DM) in the TB group (adjusted prevalence ratio 3.66, 95%CI 1.68-8.01). Among those without self-reported DM, 3.3% had glycosuria, with a number needed to screen (NNS) of 31. The NNS to find one (new) case of hypertension or proteinuria in the TB group was respectively 24 and 5. CONCLUSION:Patient-centred care that includes pragmatic NCD screening is feasible in TB patients, and the treatment period provides a good opportunity to link patients to ongoing care.
Authors: G B Migliori; F M Marx; N Ambrosino; E Zampogna; H S Schaaf; M M van der Zalm; B Allwood; A L Byrne; K Mortimer; R S Wallis; G J Fox; C C Leung; J M Chakaya; B Seaworth; A Rachow; B J Marais; J Furin; O W Akkerman; F Al Yaquobi; A F S Amaral; S Borisov; J A Caminero; A C C Carvalho; D Chesov; L R Codecasa; R C Teixeira; M P Dalcolmo; S Datta; A-T Dinh-Xuan; R Duarte; C A Evans; J-M García-García; G Günther; G Hoddinott; S Huddart; O Ivanova; R Laniado-Laborín; S Manga; K Manika; A Mariandyshev; F C Q Mello; S G Mpagama; M Muñoz-Torrico; P Nahid; C W M Ong; D J Palmero; A Piubello; E Pontali; D R Silva; R Singla; A Spanevello; S Tiberi; Z F Udwadia; M Vitacca; R Centis; L D Ambrosio; G Sotgiu; C Lange; D Visca Journal: Int J Tuberc Lung Dis Date: 2021-10-01 Impact factor: 3.427
Authors: Chuan De Foo; Pami Shrestha; Leiting Wang; Qianmei Du; Alberto L García-Basteiro; Abu Saleh Abdullah; Helena Legido-Quigley Journal: PLoS Med Date: 2022-01-18 Impact factor: 11.069
Authors: B R Adegbite; J R Edoa; Jbp Agbo Achimi Abdul; M Epola; C Mevyann; J C Dejon-Agobé; J F Zinsou; Y J Honkpehedji; S G Mpagama; A S Alabi; P G Kremsner; K Klipstein-Grobusch; A A Adegnika; M P Grobusch Journal: EClinicalMedicine Date: 2022-02-27